Fig. 3

Enthesitis/dactylitis improvements in PsA patients receiving apremilast 30 mg up to 260 weeks. Data as observed. The analysis includes all patient data, including the placebo-controlled phase, regardless of when the patients started taking apremilast (baseline, week 16, or week 24). The proportions of patients achieving a Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) of 0 (> 0 indicating enthesitis) or a dactylitis count of 0 at study visits up to week 260 are shown. Error bars represent 95% confidence interval (CI). n represents the number of patients with either MASES ≥ 1 or dactylitis count ≥ 1 at baseline and data available at that time point